JAL9 Antibody

Introduction to L9 Antibody

The L9 antibody is a human monoclonal antibody (mAb) that targets the Plasmodium falciparum circumsporozoite protein (PfCSP), a critical surface antigen on malaria-infective sporozoites. While the term "JAL9 Antibody" is not explicitly documented in available literature, extensive research exists on the L9 antibody, which may represent the intended subject due to phonetic or typographical similarity.

Epitope Specificity

L9 binds preferentially to NVDP minor repeats and cross-reacts with NANP major repeats on PfCSP . Structural analyses reveal its light chain (L9κ) is critical for cross-linking adjacent NVDP repeats, enabling high-affinity binding and neutralization of sporozoites .

In Vivo Protection

• Mouse Models: L9 reduced liver parasite load by >90% at 50 µg doses .

• Controlled Human Malaria Infection (CHMI):

  • Subcutaneous L9LS (a long-acting derivative) conferred 88% protection at serum concentrations ≥9.2 µg/mL .

  • Intravenous L9LS (20 mg/kg) achieved 100% protection in Phase 1 trials .

Comparative Efficacy

Vaccine Development

L9-inspired virus-like particle (VLP) vaccines elicit strong anti-PfCSP antibodies:

• L9 VLPs: Induced sterile protection in 57% of mice after mosquito challenge .

• Adjuvant Synergy: Co-administration with Advax-3 (CpG55.2 + alum) enhanced antibody titers .

Ongoing Research and Applications

• Phase 2 Trials: Evaluating L9LS in Mali and Kenya for 6–12 month efficacy .

• Bioconjugate Vaccines: Engineering immunogens with ≥2 NVDP repeats to mimic L9’s binding .

• Cancer Research: Unrelated CA9 antibodies (e.g., ab15086) target carbonic anhydrase IX in tumors .